Share the Video:

First responder and law enforcement perspectives on decriminalization and crisis response

Lt Diane Goldstein (Ret), Chief Joseph Montoya (DPD), Sarko Gergarian, Kate Gonella

Hear directly from the voices of first responders and law enforcement offices about the challenges and opportunities felt by people who face the frontlines of crisis situations daily. This discussion will cover the decriminalization of certain substances and its impact on crisis response, including the potential for compassionate alternatives, harm reduction strategies, and collaborative approaches that prioritize public health and community well-being. We hope to foster a nuanced understanding that paves the way for increasingly effective, more empathetic, and decreasingly coercive crisis response models.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Growing up: The next cycle of venture funding for psychedelic companies

Commercial investment dominates psychedelic sector funding, primarily for drug discovery. Non-commercial projects need financial backing for drug policy reform, public health education, harm reduction, and diversity initiatives. Strategic funding can

Daniel Goldberg, Andrew Chomer, Lindsay Hoover, Sasha Cohen

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research and Science Social Justice

Intellectual property: shadows and solutions

Traditional cultures use psychedelics, but companies are patenting therapies and compounds based on them. Discussion explores IP system improvements for innovation and public health protection.

Chris Byrnes, Laurel Kilgour, Leslie Booher

PS2023 Harm Reduction Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Giving and growth: the role of philanthropic funding in the psychedelic sector

Philanthropy and investors can support crucial psychedelic research and initiatives beyond commercial interests to shape the field and promote equity and social value in the psychedelic economy.

Sandy Samberg

PS2023 Harm Reduction Health Equity Policy and Advocacy Public Benefit Research Social Justice

The drug policy endgame: beyond public health

Seasoned leaders and activists delve into redefining drug policy, focusing on social justice, human rights, and harm reduction for a compassionate, equitable future. Join the discussion for transformative approaches.

Shaleen Title, Kassandra Frederique, Jason Ortiz

PS2023 Harm Reduction Policy and Advocacy Psychedelic Assisted Therapy Public Benefit Research and Science Substance Use Disorder

Panel discussion and Q&A with addiction researchers

Substance use disorder cases doubled during the pandemic, with over 100,000 drug overdose deaths in 2020. Research explores psychedelic-assisted therapy as a potential paradigm shift in addiction treatment efficacy.

Michael Bogenschutz, Matthew Johnson, Deborah Mash, Peter S. Hendricks

PS2023 Harm Reduction Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Proactive harm reduction by preparing set, setting, and substance

Harm reduction superheroes delve into risk mitigation and benefit maximization, exploring mindset, setting, and substances for safer drug experiences and systemic change.

Mitchell Gomez, Phoenix aka Mohawk Greene

PS2023 Health Equity Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Psychedelic social equity, criminal justice, and sentencing reform

Visionary advocates, activists, and policy experts discuss rectifying historical injustices and disparities from psychedelic criminalization. Conversations focus on social equity, criminal justice reform, and sentencing for legal infrastructure changes.

Kellen Russoniello, Rachel Knox, Sia Henry

PS2023 Policy Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Building momentum for new state policy approaches

Expansion of psychedelic policy in the US includes decriminalization, adult use regulations, and increased research funding. Elected state lawmakers discuss challenges, opportunities, and lessons from proposed psychedelic legislation.

Rep La Shawn Ford (IL), Rep Alex Dominguez (TX), Tamar Todd

PS2023 Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Designing a post-prohibition future

Harms of drug prohibition include trauma and research prevention. Policies should shift focus from criminalizing psychedelics to supporting safe, beneficial use, fostering an imaginative world for future generations.

Ariel Clark, Christopher Medina-Kirchner, Roman Haferd, Betty Aldworth, Paula Graciela Kahn

First responder and law enforcement perspectives on decriminalization and crisis response

Become a MAPS Member with a monthly donation

Related Videos